Topical Bevacizumab eyedrops for corneal neovascularisation preliminary results

TOPICAL BEVACIZUMAB EYEDROPS FOR CORNEAL

NEOVASCULARISATIONPRELIMINARY RESULTS

Siveková D., Netuková M., Liehneová K., Vokrojová M., Kuchynka P., Studený P.

Department of Ophthalmology, 3rd Medical Faculty, Charles University, Prague, Czech Republic

The authors have no financial interest in the presentation material

PurposeTo present preliminary results of using topicalBevacizumab in patients with cornealneovascularisation.

Materials and methods Prospective study – under termis and conditions of ethical

committee of 3rd Medical faculty, Charles University, Prague. All patients were fully informed and signed a consent form

14 eyes of 13 consecutive adult patients (4 men, 9 women)

Mean age 59 years (42 – 81) Follow up time 3 months

Indications in our study Pterygium 3x Leucoma corneae 4x Risk keratoplasty 4x Neovascularisation after keratitis 1x St.p. acid burn 1x

Aplication and clinical evaluation

Bevacizumab eye drops (2,5mg/ml) – OFF LABEL USE 2 times daily for 14 days

Complete ophthalmic examination including BCVA, IOP, biomicroscopy, fundus – before and after 1, 2 and 3 month

Digital photographs of the cornea Corneal pattern for grading

96 identical triangels (72 peripheral, 24 central)

Evaluation was made by 1 doctor

Aplication

Clinical evaluation

ResultsCentral segments Peripheral segments

1 2 3 4 5 6 7 8 9 10 11 12 13 140

2

4

6

8

10

12

14

16

18

20

Month 3 Month 1 Before1 2 3 4 5 6 7 8 9 10 11 12 13 14

0

10

20

30

40

50

60

70

80

Month 3 Month 1 Before

Before Month 1 Month 3Peripheral segments 28,77 24,69 23,6

Central segments 4,385 3,77 3,62

Statistically significant change 1 and 3 months after treatment in peripheral segments (p=0,003)No statistically significant change 1 and 3 months after treatment in central segments (p>0,05)

ResultsBCVA

1 2 3 4 5 6 7 8 9 10 11 12 13 140.0

0.2

0.4

0.6

0.8

1.0

1.2

Before Month 3

Before

Month 3

Month 1

Before

Month 1

Month 3

Before

Month 1

Month 3

Conclusion The short term use of Bevacizumab eye drops

seems to be very effective treatment of corneal neovascularisation

We did not note any serious complication during the therapy. In two patients we observed temporarily some small epithelial defects.

Further prospective controlled studies with larger number of patients and long term results are required.